Compass Point Lowers Sema4 (NASDAQ:SMFR) Price Target to $5.00

Sema4 (NASDAQ:SMFRGet Rating) had its target price lowered by Compass Point to $5.00 in a report issued on Monday, Stock Target Advisor reports. The brokerage currently has a na rating on the stock.

A number of other research analysts also recently commented on the company. Zacks Investment Research downgraded Sema4 from a hold rating to a sell rating in a report on Tuesday, May 10th. Cowen reduced their target price on Sema4 from $13.00 to $5.00 in a report on Monday. Finally, BTIG Research reaffirmed a buy rating and set a $8.00 target price on shares of Sema4 in a report on Friday, January 21st. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Buy and a consensus target price of $8.60.

Shares of SMFR opened at $2.00 on Monday. Sema4 has a one year low of $1.49 and a one year high of $15.21. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.77 and a quick ratio of 4.44. The stock has a 50-day moving average price of $2.58 and a 200 day moving average price of $4.06.

Sema4 (NASDAQ:SMFRGet Rating) last issued its quarterly earnings results on Monday, March 14th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.05. The business had revenue of $57.80 million during the quarter, compared to analysts’ expectations of $50.90 million. On average, equities research analysts anticipate that Sema4 will post -0.8 earnings per share for the current year.

In related news, CFO Isaac Ro sold 19,515 shares of the firm’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $2.46, for a total value of $48,006.90. Following the sale, the chief financial officer now owns 201,786 shares of the company’s stock, valued at approximately $496,393.56. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Keith A. Meister purchased 11,437,500 shares of the business’s stock in a transaction that occurred on Friday, April 29th. The stock was bought at an average cost of $4.00 per share, for a total transaction of $45,750,000.00. Following the acquisition, the director now owns 26,931,250 shares in the company, valued at approximately $107,725,000. The disclosure for this purchase can be found here. In the last three months, insiders sold 33,099 shares of company stock worth $79,156.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Morgan Stanley acquired a new stake in Sema4 in the 3rd quarter valued at approximately $27,688,000. Viking Global Investors LP acquired a new position in shares of Sema4 during the 3rd quarter valued at $22,770,000. Bleichroeder LP acquired a new position in shares of Sema4 during the 3rd quarter valued at $759,000. SB Management Ltd acquired a new position in shares of Sema4 during the 3rd quarter valued at $68,473,000. Finally, Oxbow Advisors LLC acquired a new position in shares of Sema4 during the 3rd quarter valued at $231,000.

About Sema4 (Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.

Recommended Stories

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with's FREE daily email newsletter.